<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04533867</url>
  </required_header>
  <id_info>
    <org_study_id>Beren Hacım 3</org_study_id>
    <nct_id>NCT04533867</nct_id>
  </id_info>
  <brief_title>Palonosetron vs. Ondansetron for Postoperative Nausea and Vomiting in Bariatric Surgery</brief_title>
  <official_title>Comparison of Palonosetron and Ondansetron for the Prevention of Postoperative Nausea and Vomiting After Bariatric Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bagcilar Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bagcilar Training and Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the safety and efficacy of palonosetron versus ondansetron to reduce and control&#xD;
      post-operative nausea in bariatric surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postoperative nausea and vomiting (PONV) is an undesirable clinical condition that increases&#xD;
      the likelihood of dehiscence, bleeding, pulmonary aspiration of gastric contents, and&#xD;
      electrolyte loss that lead to increased costs, prolonged hospital stays, and delayed&#xD;
      recovery. In recent years, selective serotonin 5-hydroxytryptamine sub-type 3 (5-HT3)&#xD;
      receptor antagonists such as ondansetron, granisetron, palonosetron have been introduced&#xD;
      because they are effective in the prevention and treatment of PONV in bariatric surgery. In&#xD;
      this study, the effects of ondansetron and palonosetron on PONV in patients who undergo&#xD;
      sleeve gastrectomy will be compared.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 15, 2020</start_date>
  <completion_date type="Actual">January 1, 2021</completion_date>
  <primary_completion_date type="Actual">December 15, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Week</target_duration>
  <primary_outcome>
    <measure>Nause and vomiting 6hr</measure>
    <time_frame>postoperative 6 hours</time_frame>
    <description>Visual Analog Scale score for nausea and vomiting</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nause and vomiting 24hr</measure>
    <time_frame>postoperative 24 hours</time_frame>
    <description>Visual Analog Scale score for nausea and vomiting</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nause and vomiting 48hr</measure>
    <time_frame>postoperative 48 hours</time_frame>
    <description>Visual Analog Scale score for nausea and vomiting</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nause and vomiting 72hr</measure>
    <time_frame>postoperative 72 hours</time_frame>
    <description>Visual Analog Scale score for nausea and vomiting</description>
  </primary_outcome>
  <primary_outcome>
    <measure>amount of rescue anti-emetic drugs</measure>
    <time_frame>postoperative seventh day</time_frame>
    <description>Number of anti emetic metoclopramide intravenous injections during hospitalization and the postoperative one week.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain 6hr</measure>
    <time_frame>postoperative 6 hours</time_frame>
    <description>Visual Analog Scale score for pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain 24hr</measure>
    <time_frame>postoperative 24 hours</time_frame>
    <description>Visual Analog Scale score for pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain 48hr</measure>
    <time_frame>postoperative 48 hours</time_frame>
    <description>Visual Analog Scale score for pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain 72hr</measure>
    <time_frame>postoperative 72 hours</time_frame>
    <description>Visual Analog Scale score for pain</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Functional living index- Emesis</measure>
    <time_frame>postoperative seventh day</time_frame>
    <description>Quality of life after discharge about emesis using Functional living index- Emesis</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>Nausea, Postoperative</condition>
  <condition>Vomiting, Postoperative</condition>
  <condition>Patient Reported Outcomes</condition>
  <condition>Pain, Postoperative</condition>
  <condition>Antiemetics</condition>
  <arm_group>
    <arm_group_label>Ondansetron</arm_group_label>
    <description>In Group B (n = 50): Intravenous injection of ondansetron 0.1 mg/kg diluted up to 5 mL with normal saline solution in a maximum dose of 8 mg is performed at the end of bariatric surgery while patients are in anesthesia. The drug is injected once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Palonosetron</arm_group_label>
    <description>The antiemetics used are palonosetron in Group A (n = 50): Intravenous injection of Palonosetron 1 mcg/kg diluted up to 5 mL with normal saline solution is performed at the end of bariatric surgery while patients are in anesthesia. The drug is injected once.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic sleeve gastrectomy</intervention_name>
    <description>Sleeve gastrectomy, also called a vertical sleeve gastrectomy, is a surgical weight-loss procedure. This procedure is typically performed laparoscopically, which involves inserting small instruments through multiple small incisions in the upper abdomen. During sleeve gastrectomy, about 80 percent of the stomach is removed, leaving a tube-shaped stomach about the size and shape</description>
    <arm_group_label>Ondansetron</arm_group_label>
    <arm_group_label>Palonosetron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palonosetron 1mcg/kg</intervention_name>
    <description>Injectable Palonosetron 1 mcg/kg diluted up to 5 mL with normal saline solution and injected intravenously at the end of the bariatric surgery.</description>
    <arm_group_label>Palonosetron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron 1 mg/kg, max dose 8 mg</intervention_name>
    <description>Injectable ondansetron 0.1 mg/kg, maximum of 8 mg was injected intravenously at the end of the bariatric surgery.</description>
    <arm_group_label>Ondansetron</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        obese patients underwent laparoscopic sleeve gastrectomy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All morbidity obese patients underwent laparoscopic sleeve gastrectomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        drug allergy, intractable nausea and vomiting, gastroesophageal reflux disease, pregnancy,&#xD;
        menstruation, the occurrence of nausea or vomiting episodes in the last 24 h prior to&#xD;
        surgery, the use of corticosteroids, smoking, alcoholism, the use of psychoactive drugs or&#xD;
        any other drug with antiemetic effects, hypersensitivity to other 5-HT3 antagonists,&#xD;
        emergency surgeries and chemotherapy within.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>between 18-65 years</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Ali Solmaz, Ass. Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Private Camlıca Erdem Hospital/Istanbul-TURKEY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bagcılar Training and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Surp Pırgic Armenian Hospital</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <results_reference>
    <citation>Aydin A, Kaçmaz M, Boyaci A. Comparison of ondansetron, tropisetron, and palonosetron for the prevention of postoperative nausea and vomiting after middle ear surgery. Curr Ther Res Clin Exp. 2019 Jun 22;91:17-21. doi: 10.1016/j.curtheres.2019.06.002. eCollection 2019.</citation>
    <PMID>31384338</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee S, Kim I, Pyeon T, Lee S, Song J, Rhee J, Jeong S. Population pharmacokinetics of palonosetron and model-based assessment of dosing strategies. J Anesth. 2019 Jun;33(3):381-389. doi: 10.1007/s00540-019-02641-5. Epub 2019 Apr 11.</citation>
    <PMID>30976908</PMID>
  </results_reference>
  <results_reference>
    <citation>Rajnikant K, Bhukal I, Kaloria N, Soni SL, Kajal K. Comparison of Palonosetron and Dexamethasone with Ondansetron and Dexamethasone to Prevent Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Cholecystectomy. Anesth Essays Res. 2019 Apr-Jun;13(2):317-322. doi: 10.4103/aer.AER_21_19.</citation>
    <PMID>31198253</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 9, 2020</study_first_submitted>
  <study_first_submitted_qc>August 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2020</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bagcilar Training and Research Hospital</investigator_affiliation>
    <investigator_full_name>Nadir Adnan Hacım</investigator_full_name>
    <investigator_title>Pirincipal investigator Adnan</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Palonosetron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

